Drug Overview
Zykadia (ceritinib; Novartis) is a tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK). In most ALK-positive non-small cell lung cancer (NSCLC) cases, inversions in chromosome 2 cause ALK to fuse to echinoderm microtubule-associated protein-like 4. This activates the ALK kinase domain and downstream signaling pathways responsible for excess cancer cell proliferation. ALK gene rearrangements are found more commonly in younger, non-smoking NSCLC patients and make up 3–5% of all NSCLC cases.
Zykadia (ceritinib; Novartis) is a tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK). In most ALK-positive non-small cell lung cancer (NSCLC) cases, inversions in chromosome 2 cause ALK to fuse to echinoderm microtubule-associated protein-like 4. This activates the ALK kinase domain and downstream signaling pathways responsible for excess cancer cell proliferation. ALK gene rearrangements are found more commonly in younger, non-smoking NSCLC patients and make up 3–5% of all NSCLC cases.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES